粵萬年青(301111.SZ):目前未生產或銷售直接針對基孔肯雅熱的藥品
格隆匯8月5日丨粵萬年青(301111.SZ)在互動平臺表示,公司目前未生產或銷售直接針對基孔肯雅熱的藥品。基孔肯雅熱是由基孔肯雅病毒引起,經伊蚊叮咬傳播的病毒性傳染病,其典型症狀爲發熱。公司產品中羚羊感冒膠囊功能主治清熱解表。用於流行性感冒,傷風咳嗽,頭暈發熱,咽喉腫痛。除此之外,感冒類產品還有撲感片、銀菊清解片及銀翹解毒合劑等,具體適用場景請以產品說明書或遵醫囑爲準。公司始終重視研發創新,目前公司在研產品及項目正在積極推進中,包括中藥創新藥研發和現有品種的二次開發。未來,公司將繼續加大研發投入,積極與汕頭大學等高校探索產學研合作新模式,促進協同創新,推動中醫藥現代化發展,增強公司的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.